The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2024 | EMERALD-1 trial: improved PFS w/ durvalumab + bevacizumab + TACE vs TACE in hepatocellular carcinoma
Lorenza Rimassa, MD, IRCCS Humanitas Research Hospital Rozzano, Milan, Italy, discusses the Phase III EMERALD-1 (NCT03778957) trial evaluating the combination of durvalumab (D) and bevacizumab (B) with transarterial chemoembolization (TACE) in unresectable hepatocellular carcinoma (uHCC). In this double-blind trial, participants were randomized to receive D+B+TACE, D+TACE, or TACE alone. The primary endpoint, progression-free survival (PFS), significantly improved for D+B+TACE compared to TACE alone (median PFS 15.0 vs. 8.2 months). The safety profile was manageable. D+B+TACE has the potential to become a new standard of care for uHCC. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
